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Koala retroviruses (KoRV) have been isolated from wild and captive koalas in Australia as well as from koala
populations held in zoos in other countries. They are members of the genus Gammaretrovirus, are most closely
related to gibbon ape leukemia virus (GaLV), feline leukemia virus (FeLV) and porcine endogenous retrovirus (PERV)
and are likely the result of a relatively recent trans-species transmission from rodents or bats. The first KoRV to be
isolated, KoRV-A, is widely distributed in the koala population in both integrated endogenous and infectious
exogenous forms with evidence from museum specimens older than 150 years, indicating a relatively long
engagement with the koala population. More recently, additional subtypes of KoRV that are not endogenized have
been identified based on sequence differences and host cell receptor specificity (KoRV-B and KoRV-J). A specific
association with fatal lymphoma and leukemia has been recently suggested for KoRV-B. In addition, it has been
proposed that the high viral loads found in many animals may lead to immunomodulation resulting in a higher
incidence of diseases such as chlamydiosis. Although the molecular basis of this immunomodulation is still unclear,
purified KoRV particles and a peptide corresponding to a highly conserved domain in the envelope protein have been
shown to modulate cytokine expression in vitro, similar to that induced by other gammaretroviruses. While much is still to
be learned, KoRV induced lymphoma/leukemia and opportunistic disease arising as a consequence of immunomodulation
are likely to play an important role in the stability of koala populations both in the wild and in captivity.
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Distribution of KoRVs
When an increasing incidence of lymphoma and leukemia
was recognized in koalas [1], the question was raised
whether this may be associated with a retrovirus given simi-
lar disease consequences in mice (murine leukemia virus,
MuLV) [2,3], cats (FeLV) [4,5], gibbon apes (gibbon ape
leukemia virus, GaLV) [6], and humans (human T cell
leukemia virus, HTLV) [7]. MuLV, FeLV and KoRV are
gammaretroviruses, HTLV is a deltaretrovirus and they all
belong to the subfamily Orthoretrovirinae of the family
Retroviridae. Retroviruses use the viral enzyme reverse
transcriptase to produce a double-stranded DNA copy of
the genomic RNA, which is integrated into the genome of
the target cell. This integrated form of the viral genome is
referred to as a provirus. At present, three KoRVs have* Correspondence: DennerJ@rki.de; p.young@uq.edu.au
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distribution, and reproduction in any mediumbeen described, KoRV-A, KoRV-B and KoRV-J [8-10]. The
origin of the KoRVs is still unclear, with a high probability
that they are the result of a trans-species transmission from
rodents or bats, since closely related gammaretroviruses
have been found in South Eastern Asian mice [11,12] and
bats [13,14]. It is likely that KoRV-A and GaLV, an exogen-
ous retrovirus inducing leukemia in gibbons and using the
orthogolous receptor, the sodium-dependent phosphate
transporter Pit-1, have the same origin [8]. Of note, the
lentiviruses HIV-1 and HIV-2 are also the result of a trans-
species transmission [15,16]. KoRV-B and KoRV-J have
been shown to encode an envelope gene with an altered
receptor binding domain (RBD) resulting in the use of an
alternative receptor, the thiamine transport protein 1
(THTR1) [9,10]. KoRV-A has been isolated from koalas in
Australia [8,17] and in Japanese [18,19] and German [20]
zoos. Retrovirus particles have also been described in ani-
mals at the San Diego zoo in the USA [21]. KoRV-B was
isolated from animals in the Los Angeles zoo but not fromentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Electron microscopy of KoRV grown in human cells
(Holland, Laue, Robert Koch Institute, Berlin).
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cations to the RBD have also been found in animals from
the Duisburg and Antwerpen zoos in Europe as well as
from wild koalas in Australia (our unpublished data).
KoRV-A sequences have also been found in preserved pelts
from animals kept in museums around the world [22].
KoRV-J was first isolated from a koala held in the Kobe
Municipal Oji Zoo [18]. Later, 51 animals reared in 9 differ-
ent Japanese zoos were investigated using differential PCR.
68% of the koalas sourced from northern Australia were
positive for KoRV-J, whereas none of the animals sourced
from the state of Victoria in the south of Australia were
positive for KoRV-J [10]. In a first study investigating the
prevalence of KoRV-A in the wild in Australia, a high num-
ber of infected animals were found in the North, whereas
some animals in the South, especially on Kangaroo island
were found to be negative [23]. In a later study investigating
a larger number of animals, 100% of koalas in Queensland
and New South Wales were again shown to be carrying the
virus while 14.8% (24 from 162) of the animals on
Kangaroo Island were found to be positive, suggesting
recent spread of the virus in this isolated koala population
[24]. Subsequent field studies have indicated this figure may
be as high as 30-35% (our unpublished data). The preva-
lence data must also be viewed in the context of wild koala
populations that have undergone significant upheaval in the
past. This is particularly the case for those populations in
southern Australia that were hunted to near extinction in
the late 1800s and early 1900s. Many of these areas were
subsequently repopulated by the translocation of koalas
from other localities but usually employing a relatively
small number of animals, resulting in a drastic loss of
genetic diversity [25].
Endogenization of KoRV-A
Retroviruses are divided into exogenous and endogenous
forms. Exogenous retroviruses such as the human immuno-
deficiency virus HIV-1 are transmitted horizontally through
infection of their specific somatic target cells (CD4+ T lym-
phocytes in the case of HIV-1). However when a retrovirus
infects germ cells, sperm cells or oocytes, the integrated
DNA proviruses become a fixture of the genome of all cells
of the developing organism. These are called endogenous
retroviruses and will be transmitted vertically, inherited
along with all other cellular genes [26]. While KoRV-B and
KoRV-J appear to be exogenous retroviruses given that less
than 1 copy per cell has been detected in tissues from
infected animals, KoRV-A has been found in multiple pro-
viral copies in the genome of every cell, including sperm
cells of infected animals examined in northern Australia
[23]. Its presence in sperm cells along with a host genome
integration profile that appears identical in all tissues exam-
ined from each individual, indicates that it is endogenous in
these populations [23]. However KoRV is not present inmany of the koalas sampled across southern Australia [24]
suggesting that it may currently be in the process of
endogenizing the genome of this species. This unique situ-
ation presents an exciting opportunity to study the dynamic
process of retroviral endogenization of a wild population in
real-time.
Biological properties of KoRV
The KoRVs have the typical morphology, size (KoRV-A,
Figure 1) and genome organization (Figure 2) of the
gammaretroviruses. Like all retroviruses they encode a
reverse transcriptase and structural proteins including
the main core protein p27Gag and the envelope proteins
gp70 and p15E [20]. Most studies to date have focused
on KoRV-A which has been shown to infect cells of
different species (polytropic virus) in vitro including
rat, human, feline and mink but not mouse cells
[10,19,20,27]. It was shown to infect rats in vivo, but it
remains unclear whether it is pathogenic in rats [20].
KoRV-B also infects a wide range of cells from differ-
ent species including human [9]. Using pseudotyped
KoRV-J, infection of human and cat cells was observed,
but not of rat and mouse cells [10]. Infection in vitro does
not automatically mean that these viruses can infect
in vivo and give rise to a zoonosis. For example, when the
host range of a closely related gammaretrovirus, PERV,
was investigated, no infection was observed in humans,
primates or other species when transplanting pig cells or
injecting concentrated virus, despite the fact that cells of
all species with the exception of mice could be infected
in vitro (for review see [28]).
KoRV-A, -B and -J differ in the sequence of their RBD
on the envelope protein gp70, which determines their
differential receptor use. In addition, KoRV-B has four
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Figure 2 Schematic presentation of the integrated provirus of KoRV, structure of the envelope protein and sequence of the
immunosuppressive domain. a, LTR, long terminal repeat; gag, group-specific antigen; pro-pol, protease-polymerase; env, envelope protein, FP,
fusion peptide; isu, immunosuppressive domain; MSD, membrane spanning domain; CC, cysteine-cysteine loop. The arrow indicated the cleavage
site between the surface (gp70) and the transmembrane (p15E) envelope protein. b, comparison of the sequence of the immunosuppressive
domain of three KoRV subtypes and HIV-1. Identical amino acids are in orange, conservative exchanges in lilac.
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minal repeat (LTR) that in KoRV-A is found as a single
copy [9]. The U3 region influences gene expression with
similar sequence multimerizations in the LTR of MuLV,
FeLV and PERV [29-31]. Increased numbers of repeats
correlate with increased replicative potential and hence
higher virus titers. The sequence differences in the RBD
of KoRV-A, KoRV-B and KoRV-J comprise substantial
insertion/deletions suggesting that they may be the re-
sult of recombination between KoRV-A and another en-
dogenous sequence yet to be identified.
Diseases associated with a KoRV infection
Retroviruses are known to induce tumors and/or immuno-
deficiency [3]. In some cases retroviruses are non-
pathogenic, for example the foamy viruses [32,33], while
others, such as MuLV [2,3], FeLV [4,5], GaLV [6], and
HTLV [7] induce leukemia in the corresponding host. In
addition, induced immunodeficiency often results in the
onset of disease associated with opportunistic infections.
Chlamydiosis is a major disease of koalas in both captivity
and the wild [2,34], a disease also commonly associated
with FIV (feline immunodeficiency virus) infections in cats
[35] and HIV infections in humans [36]. In general, the
diseases associated with FeLV infection in cats and KoRV
infections in koalas are very similar (see list of Diseases
reported in both FeLV-infected cats and KoRV-infected
koalas and references [1,4,5,8,17,21,34]). Whereas only 5 to10% of FeLV-infected cats suffer from leukemia and lymph-
oma, more than 65% of them die from opportunistic infec-
tion based on an underlying immunodeficiency [4,5].













It is important to note that the virus load in the blood of
KoRV positive koalas can be extremely high, reaching >109
genome equivalents/ml in some animals [37]. Virus load
has been found to correlate with disease progression, a cor-
relation typical for other retrovirus infections [38]. The
higher the virus load the higher the probability of inser-
tional mutagenesis, one possible reason for tumor induc-
tion. It will also be important to learn whether particular
KoRV subtypes are more associated with tumor develop-
ment than others. Preliminary evidence suggests such an
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load, the higher the levels of the immunomodulating trans-
membrane envelope (TM) protein p15E, implicated as a
key mediator of immunodeficiency (see below).
Does KoRV induce immunodeficiency?
Retroviruses are well known to induce immunodeficiency
[3-5,39-42] and it is interesting to note that FeLV-infected
cats as well as HIV-1-infected humans are characterized by
a decrease in the number of CD4+ cells [43]. At present it
is unknown whether KoRV infection alters the equivalent
CD4+ cell count of infected koalas or indeed any other im-
munological marker. Immunological studies in koalas have
been challenging given the absence of readily available re-
agents, however this is rapidly changing and the next few
years should see a wealth of immunological measurements
appearing in the literature.
The molecular mechanisms by which retroviruses induce
immunodeficiency are still not completely understood. But
there is accumulating evidence that the viral transmem-
brane (TM) protein, p15E, of all gammaretroviruses includ-
ing KoRV is involved. All retroviral TM proteins contain a
highly conserved sequence, referred to as the immunosup-
pressive (isu) domain (Figure 2). Viral particles and recom-
binant or native viral TM proteins of HIV-1 [44-47],
human endogenous retrovirus HERV-K [48], PERV [40,49]
and KoRV [20] have been shown to inhibit lymphocyte ac-
tivation by mitogens and modulate cytokine expression in
peripheral blood mononuclear cells (PBMCs). Single muta-
tions in the isu domain of HIV-1 gp41 abrogated the im-
munosuppressive activity of the molecule and immunization
with the mutated gp41 resulted in better antibody responses
when compared with wild-type gp41 immunization [47].
The interleukins IL-10 and IL-6 were shown to be elevated
and molecules involved in innate immunity were down-
regulated. Synthetic peptides corresponding to the isu do-
mains were able to inhibit lymphocyte activation and to
modulate gene expression in the same manner as the TM
protein and whole viruses [50-53].
Retroviral TM proteins have also been shown to be im-
munosuppressive in vivo. Transformed cells that do not
naturally develop tumors when injected into immunocom-
petent mice but do form tumors in immunocompromized
mice, could be converted into tumor forming cells
even in immunocompetent mice when TM proteins
were expressed on their surface [41,42,54-56]. The expressed
TM proteins not only prevented rejection of the transplanted
cells, but also inhibited the humoral immune response as
well as NK and CD8+ cells in the recipient animal [56,57].
The sequence of the isu domain is identical in all KoRV
subtypes so far sequenced (Figure 2) and it would be
surprising if the high viral loads carried by KoRV positive
koalas throughout their lives did not have some impact on
immune function.Impact on the life of koalas
As noted above, many gammaretroviruses are known to
cause neoplastic and immunosuppressive diseases in
their respective hosts [2-5]. The fact that koalas suffering
from lymphoma/leukemia have been shown to have
higher levels of circulating KoRV viraemia [37] and that
koalas also suffer from an unusually high incidence of
chlamydiosis, a disease associated with immunosuppres-
sion induced by gammaretroviruses in other species
[35,36], suggests that KoRV is no exception. These con-
sequences of higher levels of KoRV load are most likely
the result of an increase in the probability of mutational
insertion and/or recombination for the induction of
tumors and increased immunodeficiency. Therefore it is
not surprising that populations with low levels of KoRV
appear to have a correspondingly lower incidence of dis-
eases than those with higher viral loads [37]. Although
there is still no direct causal evidence for KoRV induced
hematopoetic neoplasia and immunosuppression, the
data published to date and comparison with other retro-
viral infections including HIV-1 strengthen the case for
an association between KoRV and disease in koalas.
There are many challenges to the life of a koala in the
wild. With an ever-expanding human population, many
koala populations live in close urban association. Conse-
quent ongoing habitat destruction, construction of roads
that transect koala habitats, and attacks from domestic
pets such as dogs pose an ever-increasing threat to
population stability. However disease poses an additional
and significant threat to koalas. Of particular concern
are the increasing rates of KoRV infection seen in some
populations [23,24] suggesting that all animals may ul-
timately become infected. If the virus becomes endogen-
ous in all animals this process is irreversible and the
virus will be transmitted to all subsequent generations.
Strategies for preventing infection and disease
To prevent the further spread of KoRV in the koala
population several strategies are potentially available; (i)
The isolation or quarantine of uninfected koalas to pre-
vent contact with infected animals. However this would
only be possible for some groups of southern koala pop-
ulations, since all populations in the north are already
carrying the virus. (ii) Antiretroviral drug treatment for
infected koalas. However the number of such drugs
available for gammaretroviruses is limited. Susceptibility
in vitro has been shown for the triphosphorylated
nucleoside analog of zidovudine (AZT), ddGTP and to a
lesser extent to ddTTP but almost no susceptibility to
the non-nucleoside RT inhibitors was observed when ac-
tivity against the related PERV was tested [58,59]. Even
if a suitable anti-retroviral could be identified, treatment
of koalas in captivity may be possible but the logistics
would likely mean little or no impact on wild koala
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vention strategies could be opportunistic vaccination.
Thousands of animals are taken into care each year
throughout Australia and then released back into the
wild. These could be vaccinated while in care. In con-
trast to HIV-1, where all attempts to generate an effect-
ive vaccine have failed, protecting vaccines against
gammaretroviruses have been successfully generated.
The best example is FeLV where commercial vaccines
exist which protect cats from virus replication and
disease, however not from infection [43,60]. Better
immunization strategies and antigens may lead to
complete protection from infection. In addition to the
vaccines against FeLV, experimental vaccines have been
developed for MuLV. These approaches have included
killed virus [61], subunit vaccines [62,63], and live atten-
uated viruses [64,65]. Immunization with the TM pro-
teins of PERV [66-68], FeLV [60,69,70] and KoRV [20
and unpublished data] induce effective neutralizing anti-
bodies mainly targeting epitopes in the membrane prox-
imal external region (MPER) of the TM protein. When
immunizing with a combination of the TM protein and
the surface envelope protein (SU) gp70 of FeLV [71,72]
and PERV [71,73], higher titers of neutralizing antibodies
were induced. In the case of FeLV it was shown that
these vaccinations protected cats from infection in vivo
[60].
Outlook
Based on immunization experiments with gamma-
retroviruses closely related to KoRV, a similar effort to in-
duce neutralizing antibodies against KoRV should be
undertaken. Prevention of infection with KoRV (preventive
vaccination) or decreasing the virus load (therapeutic treat-
ment) in already infected animals could prevent or reduce
KoRV-induced immunomodulation and therefore also pro-
tect animals from infection with chlamydia and other op-
portunistic infections. While this approach could offer
significant additional management options for koalas in
captivity, the challenge would be in the effective delivery of
such a vaccine to a wild population dispersed over a broad
geographic range.
Conclusion
The spread of a growing number of newly recognized
KoRV genotypes in both wild and captive koalas has the
potential to significantly impact the health of many koala
populations. The long-term consequences to the species
of these endogenizing elements are currently unknown.
Koalas may eventually evolve and adapt to this genomic
intruder, just as many other vertebrates, including
humans have accommodated the array of retroviral ele-
ments that make up their genomes. However in the
meantime, this relatively new and ongoing engagementbetween a group of retroviruses and their host is
resulting in the appearance in the koala population of
the same spectrum of diseases typically associated with
many exogenous retroviral infections. While there are
significant, and perhaps insurmountable logistical chal-
lenges in proposing any intervention strategies for many
wild koala populations, this may be an option for koalas
in captivity and some selected isolated wild koala popu-
lations. Both prevention and treatment strategies could
be employed. An effective vaccine or therapeutic inter-
vention would reduce virus load which in turn would
likely reduce the induction of lymphoma/leukemia and
the number and severity of opportunistic diseases arising
as a consequence of immunomodulation. A reduction in
virus load is also likely to reduce the probability of virus
transmission. As for many other retrovirus examples, a
preventive vaccine could be the best way to prevent
further spread of the virus infection. Regardless of
whether any of these strategies for control are feasible,
the ongoing process of retroviral endogenization of the
koala genome presents, for the first time an ideal op-
portunity to study this process in a wild population in
real-time.
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